Methoxsalen (Methoxsalen) Patent Expiration, LOE Window & CMS Spending

Methoxsalen (Methoxsalen) by Strides: Multi-Source Generic Molecule, 1 AB generics, $647K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorStrides
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$647K
2024 Medicare Part D Spend$541K
2024 Medicaid Spend$106K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel